Pfizer (PFE) Stock Forecast & Price Target

Pfizer logo
$28.84 -0.05 (-0.18%)
Closing price 11/16/2026 03:59 PM Eastern
Extended Trading
$28.84 +0.01 (+0.02%)
As of 05:48 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pfizer - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
2
Hold
14
Buy
6

Based on 22 Wall Street analysts who have issued ratings for Pfizer in the last 12 months, the stock has a consensus rating of "Hold." Out of the 22 analysts, 2 have given a sell rating, 14 have given a hold rating, and 6 have given a buy rating for PFE.

Consensus Price Target

$30.32
5.12% Upside
According to the 22 analysts' twelve-month price targets for Pfizer, the average price target is $30.32. The highest price target for PFE is $40.00, while the lowest price target for PFE is $25.00. The average price target represents a forecasted upside of 5.12% from the current price of $28.84.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for PFE and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Pfizer and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PFE Analyst Ratings Over Time

TypeCurrent Forecast
11/17/25 to 11/17/26
1 Month Ago
10/18/25 to 10/18/26
3 Months Ago
8/19/25 to 8/19/26
1 Year Ago
11/17/24 to 11/17/25
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
6 Buy rating(s)
5 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
Hold
14 Hold rating(s)
14 Hold rating(s)
14 Hold rating(s)
12 Hold rating(s)
Sell
2 Sell rating(s)
2 Sell rating(s)
2 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$30.32$28.72$28.28$28.28
Forecasted Upside5.12% Upside-2.88% Downside0.11% Upside12.85% Upside
Consensus RatingHoldHoldHoldHold

PFE Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PFE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Pfizer Stock vs. The Competition

TypePfizerHealthcare CompaniesBroader Market
Consensus Rating Score
2.18
2.32
2.52
Consensus RatingHoldHoldModerate Buy
Predicted Upside5.12% Upside116.15% Upside16.13% Upside
News Sentiment Rating
Neutral News

See Recent PFE News
Positive News
Positive News
Report Date
0 Results
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
11/12/2026Reiterated RatingMarket Perform$29.00-0.43%
11/9/2026
Weiss Ratings logo
Weiss Ratings
2 of 5 stars
 UpgradeHold (C) ➝ Hold (C+)
11/6/2026
FBN Securities logo
FBN Securities
2 of 5 stars
 Set Target$34.00+16.53%
11/6/2026Boost TargetBuy$33.00 ➝ $34.00+15.72%
11/6/2026 DowngradeBuy ➝ Hold
11/5/2026Boost TargetBuy$31.00 ➝ $33.00+6.15%
11/4/2026Set Target$40.00+29.90%
11/4/2026Boost TargetNeutral$27.00 ➝ $30.00-2.58%
11/4/2026Boost TargetSector Outperform$33.00 ➝ $35.00+13.66%
11/4/2026Boost TargetNeutral$27.00 ➝ $30.00-2.58%
11/4/2026Boost TargetSector Perform$25.00 ➝ $28.00-8.19%
10/9/2026Boost TargetNeutral$28.00 ➝ $30.00+6.22%
10/8/2026Boost TargetNeutral$27.00 ➝ $28.00+0.13%
9/10/2026Boost TargetHold$28.00 ➝ $30.00+7.82%
7/13/2026Lower TargetOutperform$34.00 ➝ $30.00+23.89%
7/10/2026Lower TargetNeutral$27.00 ➝ $26.00+7.24%
5/14/2026 Reiterated RatingUnderperform$26.00+0.17%
4/16/2026Initiated CoverageOutperform$33.00+21.31%
4/10/2026Boost TargetEqual Weight$27.00 ➝ $28.00+3.65%
2/24/2026 UpgradeStrong Sell ➝ Hold
2/19/2026Initiated CoverageEqual Weight ➝ Underweight$25.00-6.96%
2/12/2026 DowngradeOutperform ➝ Neutral$27.00-1.69%
12/30/2025 Reiterated RatingHold
11/5/2025Reiterated RatingNeutral$26.00+7.06%
5/29/2025 Lower TargetHold$28.00 ➝ $25.00+6.66%
5/21/2025 Boost TargetBuy$32.00 ➝ $33.00+43.11%
4/30/2025 Lower TargetNeutral$29.00 ➝ $27.00+10.61%
4/30/2025 Lower TargetMarket Perform$28.00 ➝ $26.00+6.51%
12/18/2024 Lower TargetBuy$36.00 ➝ $32.00+21.72%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 05:49 AM ET.


Should I Buy Pfizer Stock? PFE Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, November 15, 2026. Please send any questions or comments about these Pfizer pros and cons to contact@marketbeat.com.

Pfizer
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Pfizer Inc.:

  • Pfizer Inc. offers a highly attractive dividend yield of 5.95%, which is significantly higher than the broader market average, providing income-focused investors with a substantial return on their capital while the stock trades at a current price of $28.89.
  • The company recently secured up to $1.5 billion in development funding from Blackstone Life Sciences for berobenatide, its investigational monthly GLP-1 drug for obesity, which allows Pfizer to advance this high-growth therapeutic area without depleting its own cash reserves or giving up operational control of the program.
  • Pfizer Inc. demonstrated strong financial performance in its most recent quarter by beating consensus estimates with earnings per share of $0.87 and revenue of $16.58 billion, while also raising its 2026 revenue forecast by $1.5 billion, signaling management confidence in the company's future earnings trajectory.
  • With a price-to-earnings ratio of 9.47, the stock is valued at a significant discount compared to many of its pharmaceutical peers, suggesting that the market may be overpricing the risks associated with the company's pipeline and patent expirations relative to its current cash flow generation.
  • Recent analyst sentiment has shifted positively, with Wall Street Zen upgrading the stock to a "Buy" rating and other firms like Freedom Broker and Scotiabank raising their price targets to $34.00 and $35.00 respectively, indicating growing institutional confidence in the company's strategic direction.

Pfizer
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Pfizer Inc. for these reasons:

  • Despite beating earnings expectations, the stock price dropped approximately 2% following the recent quarterly results, suggesting that investors remain skeptical about the company's long-term growth prospects and are not rewarding the short-term financial beats with higher valuations.
  • Pfizer Inc. faces significant legal and financial risks from expanded patent litigation over the lipid-nanoparticle technology used in its COVID-19 vaccine, which could result in substantial licensing costs or legal liabilities that may erode future profits.
  • The company is withdrawing Premarin hormone therapy from the Canadian market following an internal review, which adds to existing menopause drug shortages and removes a revenue-generating product from a key international market, potentially impacting overall sales volume.
  • Long-term total returns have been disappointing, with a $1,000 investment from five years ago worth only $704 including reinvested dividends, indicating that the stock has underperformed significantly over the medium term despite its current high yield.
  • There is ongoing concern regarding the sustainability of the high dividend yield, as some analysts warn that record-high yields can sometimes be a warning sign of potential payout cuts if the company's free cash flow does not continue to cover the dividend with sufficient room to spare.

PFE Forecast - Frequently Asked Questions

According to the research reports of 22 Wall Street equities research analysts, the average twelve-month stock price forecast for Pfizer is $30.32, with a high forecast of $40.00 and a low forecast of $25.00.

22 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last twelve months. There are currently 2 sell ratings, 14 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" PFE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PFE, but not buy additional shares or sell existing shares.

According to analysts, Pfizer's stock has a predicted upside of 5.12% based on their 12-month stock forecasts.

Over the previous 90 days, Pfizer's stock had 2 upgrades and 1 downgrade by analysts.

Analysts like Pfizer less than other "healthcare" companies. The consensus rating score for Pfizer is 2.18 while the average consensus rating score for "healthcare" companies is 2.32. Learn more on how PFE compares to other companies.


MarketBeat monitors more than a dozen sources for Pfizer analyst ratings, with the most recent rating issued on 11/12/2026.
From Our Partners